Switch theme
Sign up to access all valuation multiples
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
2008
165
LTM Revenue $41.9M
LTM EBITDA $23.0M
$204M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
EyePoint Pharmaceuticals has a last 12-month revenue (LTM) of $41.9M and a last 12-month EBITDA of $23.0M.
In the most recent fiscal year, EyePoint Pharmaceuticals achieved revenue of $43.3M and an EBITDA of -$129M.
EyePoint Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See EyePoint Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $41.9M | XXX | $43.3M | XXX | XXX | XXX |
| Gross Profit | $39.1M | XXX | $39.6M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $23.0M | XXX | -$129M | XXX | XXX | XXX |
| EBITDA Margin | 55% | XXX | -299% | XXX | XXX | XXX |
| EBIT | -$180M | XXX | -$146M | XXX | XXX | XXX |
| EBIT Margin | -430% | XXX | -337% | XXX | XXX | XXX |
| Net Profit | -$164M | XXX | -$131M | XXX | XXX | XXX |
| Net Margin | -390% | XXX | -302% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, EyePoint Pharmaceuticals's stock price is $7.
EyePoint Pharmaceuticals has current market cap of $498M, and EV of $204M.
See EyePoint Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $204M | $498M | XXX | XXX | XXX | XXX | $-2.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, EyePoint Pharmaceuticals has market cap of $498M and EV of $204M.
EyePoint Pharmaceuticals's trades at 4.7x EV/Revenue multiple, and -1.6x EV/EBITDA.
Equity research analysts estimate EyePoint Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
EyePoint Pharmaceuticals has a P/E ratio of -3.0x.
See valuation multiples for EyePoint Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $498M | XXX | $498M | XXX | XXX | XXX |
| EV (current) | $204M | XXX | $204M | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | 8.9x | XXX | -1.6x | XXX | XXX | XXX |
| EV/EBIT | -1.1x | XXX | -1.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -3.8x | XXX | XXX | XXX |
| EV/FCF | -1.8x | XXX | -1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEyePoint Pharmaceuticals's last 12 month revenue growth is -25%
EyePoint Pharmaceuticals's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.1M for the same period.
EyePoint Pharmaceuticals's rule of 40 is -175% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
EyePoint Pharmaceuticals's rule of X is -7% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for EyePoint Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -25% | XXX | -33% | XXX | XXX | XXX |
| EBITDA Margin | 55% | XXX | -299% | XXX | XXX | XXX |
| EBITDA Growth | -178% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -175% | XXX | -323% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -7% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 307% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 428% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EyePoint Pharmaceuticals acquired XXX companies to date.
Last acquisition by EyePoint Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . EyePoint Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was EyePoint Pharmaceuticals founded? | EyePoint Pharmaceuticals was founded in 2008. |
| Where is EyePoint Pharmaceuticals headquartered? | EyePoint Pharmaceuticals is headquartered in United States of America. |
| How many employees does EyePoint Pharmaceuticals have? | As of today, EyePoint Pharmaceuticals has 165 employees. |
| Who is the CEO of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals's CEO is Dr. Jay S. Duker, M.D.. |
| Is EyePoint Pharmaceuticals publicy listed? | Yes, EyePoint Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals trades under EYPT ticker. |
| When did EyePoint Pharmaceuticals go public? | EyePoint Pharmaceuticals went public in 2008. |
| Who are competitors of EyePoint Pharmaceuticals? | Similar companies to EyePoint Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals's current market cap is $498M |
| What is the current revenue of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals's last 12 months revenue is $41.9M. |
| What is the current revenue growth of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals revenue growth (NTM/LTM) is -25%. |
| What is the current EV/Revenue multiple of EyePoint Pharmaceuticals? | Current revenue multiple of EyePoint Pharmaceuticals is 4.9x. |
| Is EyePoint Pharmaceuticals profitable? | Yes, EyePoint Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals's last 12 months EBITDA is $23.0M. |
| What is EyePoint Pharmaceuticals's EBITDA margin? | EyePoint Pharmaceuticals's last 12 months EBITDA margin is 55%. |
| What is the current EV/EBITDA multiple of EyePoint Pharmaceuticals? | Current EBITDA multiple of EyePoint Pharmaceuticals is 8.9x. |
| What is the current FCF of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals's last 12 months FCF is -$116M. |
| What is EyePoint Pharmaceuticals's FCF margin? | EyePoint Pharmaceuticals's last 12 months FCF margin is -277%. |
| What is the current EV/FCF multiple of EyePoint Pharmaceuticals? | Current FCF multiple of EyePoint Pharmaceuticals is -1.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
